Analyser av ODI Pharma

ODI Pharma AB:s (”ODI Pharma” or the ”Company”) past two quarters has been affected by import restrictions in Poland, which is now resolved,...

ODI Pharma AB (“ODI Pharma” or the ”Company”) published on February 27th the company’s Q2-report for 2024/2025.

On December 4th ODI Pharma provided an update regarding Poland’s expanding medical cannabis market.

ODI Pharma AB:s (”ODI Pharma” or the ”Company”) latest quarter was affected by import restrictions in Poland, which has been resolved after ...

ODI Pharma published on November 22nd the company’s Q1-report for 2024/2025.

ODI Pharma announced on October 30th that the company has resolved to carry out a rights issue of approximately SEK 4.

ODI Pharma AB (”ODI Pharma” or the ”Company”) delivered another strong quarter during Q4-23/24 (broken fiscal year), further proving the col...

ODI Pharma published on August 29th the company’s Q4-report for 2023/2024, which showed a continued strong momentum.

ODI Pharma announced on June 25th that the company has completed a first delivery of products to the Swiss market, a new market for ODI Phar...

The third quarter was a breakthrough quarter for ODI Pharma AB (”ODI Pharma” or the ”Company”), with net sales amounting to SEK 13.

ODI Pharma published on May 30 the company’s Q3-report for 2023/2024, which showed a strong financial development.

Analyst Group has entered into an agreement with ODI Pharma on commissioned research, including e.